Pell Bio-Med Technology Co., Ltd. (6949.TW) stock: key figures, P/E, revenue and dividend

Health Care · Taiwan

Price
36.40 TWD
Market cap
47.72 bn TWD
P/E (2025)
–
P/S (2025)
1,518.60
Dividend yield
0.00 %
Net margin
-1,349.09 %
Return on equity (ROE)
–
Return on assets (ROA)
–

Pell Bio-Med Technology Co., Ltd. financials

Fiscal year20242025
Revenue19.63 m TWD31.42 m TWD
Gross profit-12.33 m TWD-4.39 m TWD
Operating income-413.50 m TWD-467.35 m TWD
EBIT-392.97 m TWD-467.35 m TWD
Net income-389.42 m TWD-423.94 m TWD

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Pell Bio-Med Technology Co., Ltd.

Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the research, development, manufacturing, and sales of chimeric antigen recombinant T cell (CAR-T), and other related services and products. It offers autologous adipose-derived stem cell (ADSC) products to treat osteoarthritis and cartilage defects in the knee; cytokine-induced Killer cells to treat various tumors; and dendritic cell-activated cytokine-induced killer to treat solid tumors. The company is also involved in the phase 1/2 multicenter study to evaluate the safety and efficacy of CD19-targeted chimeric antigen receptor T-cell therapy in patients with relapsed or refractory B-cell lymphoma; a follow-up study of lentiviral-based gene-modified immune cell therapy. The company was founded in 2017 and is based in Taipei, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 06.11.2026. Details in the risk notice.